Deucravacitinib demonstrated superiority compared with placebo and apremilast in the treatment of adults with moderate to severe plaque psoriasis, according to findings from a phase 3 trial.
“Current therapies for plaque psoriasis, including biologics and small-molecule oral agents, are generally efficacious but physicians often have to choose between efficacy, safety and patient convenience when recommending treatments,” Bruce Strober, MD, PhD, clinical professor of dermatology at Yale University School of Medicine, and colleagues wrote. “Therefore, novel, oral targeted